BioVie Inc
Change company Symbol lookup
Select an option...
BIVI BioVie Inc
PNR Pentair PLC
AAL American Airlines Group Inc
AMD Advanced Micro Devices Inc
IDAI T Stamp Inc
VZ Verizon Communications Inc
CETX Cemtrex Inc
RNXT RenovoRx Inc
BNTX BioNTech SE
ARTW Art's Way Manufacturing Co Inc
Go

Health Care : Biotechnology | Small Cap Blend
Company profile

BioVie Inc. is a clinical-stage company. The Company is developing drug therapies to treat chronic debilitating conditions, including liver disease and neurological and neuro-degenerative disorders and certain cancers. In liver disease, the Company's orphan drug candidate BIV201 (continuous infusion terlipressin) is developed as a future treatment option for patients suffering from ascites and other life-threatening complications of advanced liver cirrhosis caused by nonalcoholic steatohepatitis (NASH), hepatitis, and alcoholism. The Company is also engaged in developing NE3107, an extracellular single-regulated kinase (ERK) inhibitor that selectively reduces neuroinflammation and insulin resistance. NE3107 is an orally administered small molecule to inhibit inflammation-driven insulin resistance and pathological inflammatory cascades.

Price
Delayed
$8.70
Day's Change
0.2299 (2.71%)
Bid
--
Ask
--
B/A Size
--
Day's High
8.97
Day's Low
8.37
Volume
(Light)

Today's volume of 99,963 shares is on pace to be much lighter than BIVI's 10-day average volume of 601,367 shares.

99,963
  • Prev Close
    8.47
  • Today's Open
    8.55
  • Day's Range
    8.37-8.97
  • Avg Vol (10-day)
    601.4K
  • Last (time)
    11:56a ET 03/28/23
  • Last (size)
    100
  • 52-Wk Range
    1.33 - 14.38
    LowHigh
  • (07/01/22 - 12/16/22)
    39.50%
  • 142.0%
  • Market Cap
    301.6M
  • Shares Outstanding
    35.0M
  • -1.49
  • --
  • No dividend
  • Ex-dividend Date
    No dividend
  • Dividend Pay Date
    No dividend
  • 2.5
  • 3.76
  • (% of float 02/28/23)
    3.25

Latest News

March 24, 2023
8:30 am ET
Accesswire
March 21, 2023
8:01 am ET
Globe Newswire
March 14, 2023
8:00 am ET
Globe Newswire
March 13, 2023
8:00 am ET
Globe Newswire
March 09, 2023
8:00 am ET
Globe Newswire
March 06, 2023
8:00 am ET
Globe Newswire
March 02, 2023
8:00 am ET
Globe Newswire
February 21, 2023
8:00 am ET
Globe Newswire
January 25, 2023
8:01 am ET
Accesswire
December 29, 2022
8:30 am ET
Accesswire
December 08, 2022
4:25 pm ET
MarketWatch
Go to all current & historical news

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.